Capital Group Companies Inc Form 8.3 - Horizon Therapeutics PLC (7919I)
2022年12月6日 - 10:42PM
ＲＮＳを含む英国規制内ニュース （英語）
TIDM0A2V TIDMTTM
RNS Number : 7919I
Capital Group Companies Inc
06 December 2022
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT,
1997,
TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES
REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing The Capital Group Companies, Inc.
Company dealt in Horizon Therapeutics PLC
-----------------------------------------------
Class of relevant security to which US$0.0001 ordinary shares (IE00BQPVQZ61)
the
dealings being disclosed relate
-----------------------------------------------
Date of dealing 05 December 2022
-----------------------------------------------
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of
relevant security
dealt in
Long Short
Number (%) Number (%)
--------------------- ---------- ------------- -----------
(1) Relevant securities 10,076,263 shares 4.45 %
--------------------- ---------- ------------- -----------
(2) Derivatives (other than
options):
---- ---------------------------- --------------------- ---------- ------------- -----------
(3) Options and agreements
to purchase/sell:
---- ---------------------------- --------------------- ---------- ------------- -----------
Total 10,076,263 shares 4.45 %
---- ---------------------------- --------------------- ---------- ------------- -----------
(b) Interests and short positions in relevant securities of the company,
other than the
class dealt in
Class of relevant security: Long Short
Number (%) Number (%)
--------------------- ---------- ------------- -----------
(1) Relevant securities
---- ---------------------------- --------------------- ---------- ------------- -----------
(2) Derivatives (other than
options):
---- ---------------------------- --------------------- ---------- ------------- -----------
(3) Options and agreements
to purchase/sell:
---- ---------------------------- --------------------- ---------- ------------- -----------
Total
---- ---------------------------- --------------------- ---------- ------------- -----------
3. DEALINGS
(a) Purchases and sales
Purchase/sale Number of relevant Price per unit
securities
Purchase 448 shares 98.4800 - USD
------------------------------------ ----------------------------
Purchase 118 shares 104.8500 - USD
------------------------------------ ----------------------------
Purchase 76 shares 98.8150 - USD
------------------------------------ ----------------------------
Purchase 47 shares 99.0151 - USD
------------------------------------ ----------------------------
Purchase 23 shares 99.0347 - USD
------------------------------------ ----------------------------
Sale 9,999 shares 100.1861 - USD
------------------------------------ ----------------------------
(b) Derivatives transactions (other than options transactions)
Product name Nature of transaction Number of relevant Price per unit
e.g. CFD securities
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name Writing, Number of Exercise Type, Expiry Option money
e.g. call option purchasing, securities price e.g. American, date paid/ received
selling, to which European per unit
varying the option etc.
etc. relates
(ii) Exercising
Product name Number of securities Exercise price per unit
e.g. call option
(d) Other dealings (including subscribing for new securities)
Nature of transaction Details Price per unit (if applicable)
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the
person disclosing and any other person relating to the voting rights of
any relevant securities under any option referred to on this form or relating
to the voting rights or future acquisition or disposal of any relevant
securities to which any derivative referred to on this form is referenced.
If none, this should be stated.
None
Is a Supplemental Form 8 attached? NO
Date of disclosure 06 December 2022
Contact name Art Romero
--------------------------------
Telephone number 213 452 2709
--------------------------------
If a connected EFM, name of offeree/offeror
with which connected
--------------------------------
If a connected EFM, state nature of connection
--------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ISEBKABQNBDDDBK
(END) Dow Jones Newswires
December 06, 2022 08:42 ET (13:42 GMT)
Sanofi (LSE:0A2V)
過去 株価チャート
から 11 2024 まで 12 2024
Sanofi (LSE:0A2V)
過去 株価チャート
から 12 2023 まで 12 2024
